(Watch the video interview HERE)
Mo Khan, chief executive of hVIVO (HVO), talks to Vox Markets about the company’s latest contract win, a £13.1m deal to develop a human challenge model for Influenza B with an existing client, and how the approach is gathering momentum across the industry.
0:36 Details of the new £13.1m contract with an existing big pharma client to
develop a new human challenge model for influenza B.
2:25 How human challenge models are helping the industry develop highly-
targeted treatments, and enabling fast-tracked regulatory approval.
4:28 Next steps in the development of the influenza B human challenge model,
and the ability to leverage the model in future.
6:18 The challenges presented in developing influenza treatments, and how
human challenge models can help to bring flu under control.